| scholarly article | Q13442814 |
| P356 | DOI | 10.5966/SCTM.2013-0132 |
| P8608 | Fatcat ID | release_smwuqw7rpraidjbqytlyan56fe |
| P932 | PMC publication ID | 3925057 |
| P698 | PubMed publication ID | 24436439 |
| P2093 | author name string | Sin-Soo Jeun | |
| Chang Hyun Jeong | |||
| Chung Heon Ryu | |||
| Seong Muk Kim | |||
| Jae-Deog Jang | |||
| Ji Sun Woo | |||
| P2860 | cites work | Irradiation Enhances the Tumor Tropism and Therapeutic Potential of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Secreting Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Glioma Therapy | Q39644411 |
| TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors | Q39645187 | ||
| Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells | Q39649739 | ||
| Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma | Q39910399 | ||
| Mechanisms of resistance of human glioma cells to Apo2 ligand/TNF-related apoptosis-inducing ligand | Q40114772 | ||
| Cancer gene therapy using a novel secretable trimeric TRAIL. | Q40367155 | ||
| Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model | Q40508031 | ||
| Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. | Q40975748 | ||
| Identification of c-FLIP(L) and c-FLIP(S) as critical regulators of death receptor-induced apoptosis in pancreatic cancer cells | Q42874678 | ||
| Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy | Q43100976 | ||
| Complete regression of metastatic renal cell carcinoma by multiple injections of engineered mesenchymal stem cells expressing dodecameric TRAIL and HSV-TK. | Q45883468 | ||
| Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety | Q46661382 | ||
| Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer | Q60620763 | ||
| Barriers to effective TRAIL-targeted therapy of malignancy | Q81375289 | ||
| A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies | Q82847250 | ||
| Inhibition of death receptor signals by cellular FLIP | Q24316446 | ||
| Identification and characterization of a new member of the TNF family that induces apoptosis | Q24318423 | ||
| X-linked IAP is a direct inhibitor of cell-death proteases | Q24318710 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide | Q33341259 | ||
| Safety and antitumor activity of recombinant soluble Apo2 ligand | Q33855449 | ||
| Enhanced proapoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand on temozolomide-resistant glioma cells | Q34618860 | ||
| TRAIL receptor signalling and modulation: Are we on the right TRAIL? | Q34913133 | ||
| RNA interference targeting survivin exerts antitumoral effects in vitro and in established glioma xenografts in vivo | Q35225270 | ||
| Cisplatin restores TRAIL apoptotic pathway in glioblastoma-derived stem cells through up-regulation of DR5 and down-regulation of c-FLIP. | Q35665706 | ||
| Mechanisms of resistance to TRAIL-induced apoptosis in cancer | Q35954258 | ||
| Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy. | Q36072501 | ||
| Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis | Q36084509 | ||
| Genetic strategies for brain tumor therapy | Q36247099 | ||
| Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy | Q37140126 | ||
| Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). | Q37221909 | ||
| TRAIL gene therapy: from preclinical development to clinical application | Q37307340 | ||
| Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide | Q37356520 | ||
| Review: on TRAIL for malignant glioma therapy? | Q37681647 | ||
| Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy | Q39245228 | ||
| Effective combination therapy for malignant glioma with TRAIL-secreting mesenchymal stem cells and lipoxygenase inhibitor MK886. | Q39282411 | ||
| CXC chemokine receptor 1 enhances the ability of human umbilical cord blood-derived mesenchymal stem cells to migrate toward gliomas | Q39570178 | ||
| A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models | Q39630653 | ||
| P433 | issue | 2 | |
| P921 | main subject | gene therapy | Q213901 |
| temozolomide | Q425088 | ||
| mesenchymal stem cell | Q1922379 | ||
| P304 | page(s) | 172-182 | |
| P577 | publication date | 2014-01-16 | |
| P1433 | published in | Stem Cells Translational Medicine | Q26842216 |
| P1476 | title | Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma | |
| P478 | volume | 3 |
| Q38227489 | Advances in stem cells, induced pluripotent stem cells, and engineered cells: delivery vehicles for anti-glioma therapy |
| Q41983273 | Clinical and prognostic significance of high-mobility group box-1 in human gliomas |
| Q39556636 | Combined treatment, based on lysomustine administration with mesenchymal stem cells expressing cytosine deaminase therapy, leads to pronounced murine Lewis lung carcinoma growth inhibition |
| Q33757933 | Conditioned media from human adipose tissue-derived mesenchymal stem cells and umbilical cord-derived mesenchymal stem cells efficiently induced the apoptosis and differentiation in human glioma cell lines in vitro |
| Q27026414 | Engineering mesenchymal stem cells for regenerative medicine and drug delivery |
| Q41709256 | Human menstrual blood-derived mesenchymal stem cells as a cellular vehicle for malignant glioma gene therapy |
| Q36402844 | In vivo near-infrared imaging for the tracking of systemically delivered mesenchymal stem cells: tropism for brain tumors and biodistribution |
| Q64277474 | Magnetic ternary nanohybrids for nonviral gene delivery of stem cells and applications on cancer therapy |
| Q57174410 | Mesenchymal Stem Cell Expressing TRAIL as Targeted Therapy against Sensitised Tumour |
| Q47109590 | Mesenchymal stem cells as therapeutic agents and in gene delivery for the treatment of glioma*. |
| Q53269695 | Neural differentiation of mesenchymal stem cells influences their chemotactic responses to stromal cell-derived factor-1α. |
| Q39725955 | Non-virally engineered human adipose mesenchymal stem cells produce BMP4, target brain tumors, and extend survival |
| Q37641600 | Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide |
| Q58805856 | Renal Ischemia-Reperfusion Injury in a Diabetic Monkey Model and Therapeutic Testing of Human Bone Marrow-Derived Mesenchymal Stem Cells |
| Q28076798 | Role of nanotechnology and gene delivery systems in TRAIL-based therapies |
| Q38521752 | Stem cell in alternative treatments for brain tumors: potential for gene delivery |
| Q38245163 | Stem cell-based therapies for cancer treatment: separating hope from hype |
| Q38855638 | Stem cell-based therapies for tumors in the brain: are we there yet? |
| Q47142453 | Stem cells in cancer therapy: opportunities and challenges |
| Q59807366 | Sulforaphane from Cruciferous Vegetables: Recent Advances to Improve Glioblastoma Treatment |
| Q42479312 | Temozolomide sensitizes stem-like cells of glioma spheres to TRAIL-induced apoptosis via upregulation of casitas B-lineage lymphoma (c-Cbl) protein |
| Q38213836 | Therapeutic cell carriers: a potential road to cure glioma |
| Q42368100 | pIL6-TRAIL-engineered umbilical cord mesenchymal/stromal stem cells are highly cytotoxic for myeloma cells both in vitro and in vivo |
Search more.